Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients at 24 weeks to stop PegIFN/RBV or continue PegIFN/RBV until week 48. If no ETS, then PegIFN/RB for 48 weeks, in HCV treatment-naive or relapsers patients coinfected with HIV

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim

Criteria

Inclusion criteria:

1. Chronic hepatitis C (HCV) genotype 1 infection

2. Chronic Human Immunodeficiency Virus (HIV) -1 infection

3. HCV treatment naive or HCV treatment experienced but only relapsers

4. Age 18 to 70 years

5. Antiretroviral treatment naive or on stable Highly Active Antiretroviral Therapy (HAART)

6. Karnofsky score >70

7. HCV viral load >1.000 IU/mL

Exclusion criteria:

1. HCV infection of mixed genotype (1/2, 1/3, 1/4)

2. Evidence of acute or chronic liver due to chronic HCV infection

3. Hepatitis B virus (HBV) infection with presence of HBs-Ag

4. Active malignancy or history or malignancy within the last 5 years

5. Received concomitant systemic antiviral (other than antiretroviral), hematopoietic growth factor or immunomodulatory treatment in 28 days prior enrolment.

6. Decompensated liver disease,as evidenced by ascites, hepatic encephalopathy, esophageal variceal bleeding, and/or laboratory values that add up to >/= 7 points according tho the Child-Turcotte-Pugh classification

7. Hemoglobin

8. Patients with stable cardiac disease and Hemoglobin <12g/dL

9. Known hypersensitivity to any ingredient of the study drugs